Flt3L mRNA Immune Priming Without Protein Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional protein-based formulations of Flt3L are associated with side effects such as anaphylactic responses and reduced therapeutic efficiency due to antibody formation, and are time-consuming and expensive to produce, limiting their effectiveness in enhancing immune responses for diseases like cancer and infectious diseases.
Innovation Solution
Utilizing mRNA encoding for Flt3L protein or functional fragments, delivered via naked RNA, lipid nanoparticles, or expression vectors, to enhance immune responses without the drawbacks of protein-based methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-based formulations of Flt3L are used, then immune response enhancement is achieved, but side effects such as anaphylactic responses and antibody formation occur
Solution Approach 1:
The patent changes the molecular form of Flt3L from protein to mRNA encoding the protein. This parameter change allows the body to produce the therapeutic protein endogenously through cellular translation, avoiding direct administration of foreign proteins that trigger anaphylactic responses and antibody formation, while maintaining the immune-enhancing effects
Solution Approach 2:
Instead of administering the actual Flt3L protein, the patent uses mRNA as a copy or blueprint that instructs cells to produce the protein themselves. This indirect approach avoids the harmful immune reactions to exogenous proteins while achieving the same therapeutic effect through endogenous protein production
2Reliability
If protein-based formulations of Flt3L are used, then immune response enhancement is achieved, but production is time-consuming and expensive
Solution Approach 1:
The patent uses mRNA as a informational copy that can be rapidly synthesized and scaled without the complex cell culture processes required for protein production. mRNA can be produced in vitro through transcription, allowing for faster and more cost-effective manufacturing while maintaining therapeutic efficacy
Solution Approach 2:
The patent replaces the mechanical/biological system of protein production (cell culture, purification, formulation) with a simpler chemical transcription process to generate mRNA. This substitution dramatically reduces production time and cost while maintaining the ability to achieve the desired immune response enhancement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mRNA-based approach avoids side effects, ensures therapeutic efficiency, and provides a more tolerable and cost-effective strategy for boosting immunity, recruiting immune cells like DCs and B cells, and enhancing antigen-specific T cell responses.
Implementation Method 1
The hematopoietic cytokine fms-like tyrosine kinase 3 ligand (Flt3L) is a growth factor that has been widely identified as a strong stimulator in the generation of B cells and dendritic cells (DCs)
Implementation Method 2
Flt3L administration has been suspected to be also responsible for the expansion in the numbers of natural killer (NK) cells and T lymphocytes
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
The present invention relates to an mRNA encoding for an Flt3L protein or a functional fragment thereof for use in enhancing an immune response in a subject. The present invention further relates to a pharmaceutical composition, comprising the mRNA or the functional fragment thereof for use in medicine, in particular for a use in enhancing an immune response in a subject. The use comprises a combination prevention or therapy, such as, for example, a pre-treatment to improve vaccines against infectious diseases or cancer, or for enhancing an anticancer treatment in combination with at least one anticancer monoclonal antibody. The present invention further relates to a method for enhancing an immune response in a subject, comprising administering an effective amount of the mRNA encoding for an Flt3L protein or a functional fragment thereof according to the invention to the subject.